Get the Stockscreener App
37.49
4.58%
-1.80
Ultragenyx Pharmaceutical Inc stock is traded at $37.49, with a volume of 1.09M.
It is down -4.58% in the last 24 hours and up +5.90% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$39.29
Open:
$38.34
24h Volume:
1.09M
Relative Volume:
1.14
Market Cap:
$3.51B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-5.7944
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
+0.87%
1M Performance:
+5.90%
6M Performance:
-18.11%
1Y Performance:
-13.06%
1-Day Range:
$37.13
$39.33
1-Week Range:
$36.13
$40.19
52-Week Range:
$29.59
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
37.49 | 3.51B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
FDA approves Ultragenyx's Mepsevii in mucopolysaccharidosis type VII enzyme disorder - FirstWord
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - marketscreener.com
Ultragenyx (RARE) Q1 2025 Performance Shows Resilience - GuruFocus
Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com
How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com
Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq
Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN
William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus
William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com
William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com
Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus
Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan
Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN
Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus
(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmace - GuruFocus
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmaceutical | RARE Stock News - GuruFocus
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ultragenyx Pharmaceutical Inc Stock (RARE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Crombez Eric | EVP and Chief Medical Officer |
Apr 21 '25 |
Sale |
35.11 |
242 |
8,497 |
71,680 |
| Horn Howard | Chief Financial Officer |
Mar 06 '25 |
Sale |
40.40 |
1,785 |
72,114 |
106,169 |
| Kassberg Thomas Richard | CBO & EVP |
Mar 03 '25 |
Sale |
42.10 |
6,028 |
253,779 |
265,238 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Mar 03 '25 |
Sale |
42.10 |
12,846 |
540,817 |
75,287 |
| Crombez Eric | EVP and Chief Medical Officer |
Mar 03 '25 |
Sale |
42.10 |
8,945 |
376,584 |
71,922 |
| Pinion John Richard | See Remarks |
Mar 03 '25 |
Sale |
42.10 |
14,439 |
607,882 |
107,766 |
| KAKKIS EMIL D | President & CEO |
Mar 03 '25 |
Sale |
42.10 |
73,434 |
3,091,571 |
641,731 |
| KAKKIS EMIL D | President & CEO |
Feb 28 '25 |
Sale |
42.48 |
25,000 |
1,062,000 |
2,158,985 |
| Harris Erik | EVP & Chief Commercial Officer |
Mar 03 '25 |
Sale |
42.10 |
15,103 |
635,836 |
87,855 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Mar 03 '25 |
Sale |
42.10 |
967 |
40,711 |
50,265 |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):